Mastologia

Lesões de células mamárias fusiformes: algoritmo diagnóstico.

29 Ago, 2022 | 13:40h

Spindle Cell Lesions of the Breast: A Diagnostic Algorithm – Archives of Pathology & Laboratory Medicine

 

---

Estudo randomizado | Doses de radiação e esquemas de fracionamento no carcinoma ductal in situ mamário de não baixo risco.

10 Ago, 2022 | 14:28h

Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study – The Lancet (link para o resumo – $ para o texto completo)

 

---

Estudo de coorte | Impacto do status baixo vs. negativo do receptor de estrogênio/progesterona sobre as características clínico-patológicas e os desfechos de sobrevida no câncer de mama HER2-negativo.

10 Ago, 2022 | 14:10h

Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer – npj Breast Cancer

 

Comentário no Twitter

Out on NPJ Breast a new report on #ERlowtumors. No difference in characteristics, pCR rates, RFS os OS compared with #TNBC. Patients with ER-low tumors should be treated as for TNBC. Also, important confounder to remember in HER2-low prognostic analyses.https://t.co/M1GF8eyYbT pic.twitter.com/CrLyUgyhUV

— Paolo Tarantino (@PTarantinoMD) July 11, 2022

 

---

Estudo randomizado | Irradiação mamária parcial vs. total para câncer de mama precoce.

9 Ago, 2022 | 17:16h

Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)

 

---

Diretriz NCCN atualizada | Câncer de mama.

21 Jun, 2022 | 12:58h

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

---

Estudo de coorte | Associação do rastreamento com tomossíntese digital de mama vs. mamografia digital com o risco de câncer de mama avançado e invasivo.

19 Jun, 2022 | 17:12h

Association of Screening With Digital Breast Tomosynthesis vs Digital Mammography With Risk of Interval Invasive and Advanced Breast Cancer – JAMA (gratuito por tempo limitado)

Editorial: Digital Breast Tomosynthesis and Detection of Interval Invasive and Advanced Breast Cancers – JAMA (gratuito por tempo limitado)

Comunicado de imprensa: 3-D Mammography Technique Benefits Some Women, Not All – University of California San Francisco

---

Breve resumo dos principais fatos atuais e recomendações | Linfadenopatia regional após vacinação contra COVID-19 em pacientes com ou sem suspeita de câncer de mama.

19 Jun, 2022 | 14:21h

Regional Lymphadenopathy Following COVID-19 Vaccination in Patients with or Suspicious of Breast Cancer: A Quick Summary of Current Key Facts and Recommendations – Korean Journal of Radiology

Conteúdos relacionados:

2 Case Series and Guidance | Lymphadenopathy in COVID-19 Vaccine Recipients

Axillary lymphadenopathy at the time of COVID-19 vaccination: ten recommendations from the European Society of Breast Imaging (EUSOBI) – Insights into Imaging

Covid-19: Schedule breast screening before vaccine or 4 to 6 weeks after to avoid false positives, says guidance – The BMJ

Frequency and outcomes of MRI-detected axillary adenopathy following COVID-19 vaccination – European Radiology

Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care – European Journal of Cancer

---

DNA circulante de tumor e recorrência tardia em câncer de mama de alto risco, positivo para receptor de hormônio e negativo para receptor do fator de crescimento epidérmico humano 2.

19 Jun, 2022 | 13:04h

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer – Journal of Clinical Oncology

Editorial: Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor–Positive Early Breast Cancer?

Comentário: Tumor DNA Assay Portends Metastatic Breast Cancer Recurrence Months in Advance — First evidence for patients in late adjuvant setting, years after initial diagnosis – MedPage Today (necessário cadastro gratuito)

 

Comentário no Twitter

103 women in long-term remission from high-risk HR+/HER2- breast cancer had customized monitoring of recurrence based on ctDNA seq for tumour-associated mut. Among 8 pts MRD+ pts, 6 developed distant recurrence at a median 12.4 mo after ctDNA positivity https://t.co/aX1ruLCSbb

— NatureRevClinOncol (@NatRevClinOncol) June 9, 2022

 

---

Estudo de coorte | Qualidade de vida de longo prazo em pacientes com câncer de mama após conservação da mama vs. mastectomia e reconstrução.

16 Jun, 2022 | 12:47h

Long-term Quality of Life in Patients With Breast Cancer After Breast Conservation vs Mastectomy and Reconstruction – JAMA Surgery (link para o resumo – $ para o texto completo)

Comentários:

Long-Term QOL Examined for Surgical Choices in Breast Cancer – HealthDay

Improved Long-Term Quality-of-Life Measures in Women Undergoing Breast Conservation vs Mastectomy and Reconstruction for Early Breast Cancer – The ASCO Post

 

Comentário no Twitter

Survey of #breastcancer survivors after treatment found:
1. Breast satisfaction and physical well-being similar with lumpectomy+rads or mastectomy+reconstruction (no rads)
2. Psychosocial well-being and sexual well-being better with lumpectomy+rads https://t.co/tPh9Pt4gYx

— JAMA Surgery (@JAMASurgery) April 14, 2022

 

---

Estudo randomizado de fase 2 | Eficácia do epigalocatecina-3-galato na prevenção de dermatites em pacientes com câncer de mama sob radioterapia pós-cirúrgica.

6 Jun, 2022 | 11:11h

Efficacy of Epigallocatechin-3-Gallate in Preventing Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy: A Double-Blind, Placebo-Controlled, Phase 2 Randomized Clinical Trial – JAMA Dermatology (gratuito por tempo limitado)

Resumo visual: Efficacy of Epigallocatechin-3-Gallate on Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy

---